VanEck Vectors Biotech ETF (BBH)
126.78
+1.26 +1.00%
NASDAQ
Aug 19, 20:00
Delayed 2m
USD
Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
| 1 Year Fund Level Flows | Upgrade |
View All BBH News
News
-
WireHeadlineTime (ET)
-
Yahoo08/06 16:22
-
Yahoo06/26 11:00
-
Yahoo06/19 11:49
-
SA Breaking News06/17 13:21
-
SA Breaking News01/02 04:34
-
SA Breaking News11/28 09:43
-
Business Wire11/16 17:52
-
SA Breaking News10/31 09:03
-
SA Breaking News10/25 14:32
-
Business Wire10/17 11:48
Performance & Returns
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 1.67% | 1.49% | -1.94% | 5 |
| 3M | 5.61% | 5.48% | 2.00% | 32 |
| 6M | -1.30% | -1.35% | -2.09% | 64 |
| YTD | 14.51% | 13.82% | 10.33% | 31 |
| 1Y | -1.53% | -1.54% | -3.17% | 57 |
| 3Y | 3.69% | 3.67% | 8.44% | 85 |
| 5Y | 4.53% | 4.52% | 8.30% | 83 |
| 10Y | -- | -- | 14.69% | -- |
| 15Y | -- | -- | 11.00% | -- |
| 20Y | -- | -- | 10.08% | -- |
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | -0.05% | 0.00% | 0.05% |
| Stock | 100.0% | 100.0% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
Region Exposure
| Americas | 92.90% |
| North America | 92.90% |
| Latin America | 0.00% |
| Greater Europe | 2.66% |
| United Kingdom | 0.00% |
| Europe Developed | 2.66% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.00% |
| Greater Asia | 4.44% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.00% |
| Asia Emerging | 4.44% |
| Market Classification | |
| % Developed Markets | 95.56% |
| % Emerging Markets | 4.44% |
Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.00% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 100.0% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.00% |
| Utilities | 0.00% |
Stock Market Capitalization
| Giant | 10.84% |
| Large | 55.47% |
| Medium | 32.47% |
| Small | 1.21% |
| Micro | 0.00% |
Stock Style Exposure
| Large Cap Value | 30.79% |
| Large Cap Blend | 15.78% |
| Large Cap Growth | 18.14% |
| Mid Cap Value | 0.00% |
| Mid Cap Blend | 0.00% |
| Mid Cap Growth | 34.02% |
| Small Cap Value | 0.00% |
| Small Cap Blend | 1.27% |
| Small Cap Growth | 0.00% |
View More Holdings
As of Aug. 19, 2019
Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| AMGN | Amgen Inc | 10.85% | 203.03 | -1.44% |
| GILD | Gilead Sciences Inc | 7.43% | 63.52 | -0.92% |
| CELG | Celgene Corp | 6.85% | 95.40 | +0.19% |
| AGN | Allergan PLC | 6.23% | 159.38 | +0.08% |
| IQV | IQVIA Holdings Inc | 5.36% | 155.01 | -1.09% |
| VRTX | Vertex Pharmaceuticals Inc | 5.25% | 183.04 | -2.16% |
| BIIB | Biogen Inc | 4.90% | 230.97 | -2.02% |
| INCY | Incyte Corp | 4.80% | 84.14 | -0.45% |
| BGNE | BeiGene Ltd ADR | 4.55% | 146.16 | -1.44% |
| EXAS | Exact Sciences Corp | 4.53% | 119.94 | +1.51% |
Advertisement
One Page Reports
- One Page Report Download
Basic Info
| Style | |
|---|---|
| Equity Style | Large Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | VanEck |
| Benchmark Index | |
|---|---|
MVIS US Listed Biotech 25 NR USD |
100.0% |
Manager Info
| Name | Tenure |
|---|---|
| Guo Hua (Jason) Jin | 1.33 yrs |
| Hao-Hung (Peter) Liao | 7.45 yrs |
Net Fund Flows
| 1M | -6.350M |
| 3M | -36.72M |
| 6M | -56.01M |
| YTD | -61.95M |
| 1Y | -91.96M |
| 3Y | -287.91M |
| 5Y | -259.45M |
| 10Y | -- |
Risk Info
| Beta (5Y) | 1.352 |
| Max Drawdown (All) | 33.76% |
| Historical Sharpe Ratio (10Y) | -- |
| Historical Sortino (All) | 1.32 |
| 30-Day Rolling Volatility | 17.38% |
| Daily Value at Risk (VaR) 1% (All) | 3.76% |
| Monthly Value at Risk (VaR) 1% (All) | 15.02% |
Fundamentals
| Dividend Yield TTM (8-19-19) | 0.43% |
| 30-Day SEC Yield (10-30-15) | 0.24% |
| 7-Day SEC Yield | -- |
| Weighted Average PE Ratio | 18.59 |
| Weighted Average Price to Sales Ratio | 5.504 |
| Weighted Average Price to Book Ratio | 3.950 |
| Weighted Median ROE | 18.42% |
| Weighted Median ROA | 4.64% |
| Forecasted Dividend Yield | 0.85% |
| Forecasted PE Ratio | 14.28 |
| Forecasted Price to Sales Ratio | 4.902 |
| Forecasted Price to Book Ratio | 3.381 |
| Number of Holdings | 27 |
Growth Estimates
| Forecasted 5 Yr Earnings Growth | 10.58% |
| Forecasted Book Value Growth | 7.42% |
| Forecasted Cash Flow Growth | 6.60% |
| Forecasted Earnings Growth | 18.70% |
| Forecasted Revenue Growth | 8.78% |
Attributes
| Key Dates | |
|---|---|
| Inception Date | 12/20/2011 |
| Termination Date | |
| Last Annual Report Date | 9/30/2018 |
| Last Prospectus Date | 2/1/2019 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
Excel Add-In Codes
- Name: =YCI("BBH","name")
- Broad Asset Class: =YCI("BBH", "broad_asset_class")
- Broad Category: =YCI("BBH", "broad_category_group")
- Prospectus Objective: =YCI("BBH", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
